Christine Coughlin, MD, PhD, on TRACK-NK Technology in Non-Small Cell Lung Cancer

Video

The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.

“Monoclonal antibodies combined with the patient's own endogenous response can have efficacy in some tumors. Many patients’ endogenous immune system has been really trampled on by all the chemotherapy that they receive. So, based on some early data that have come out with allogeneic NK cells, we think combining an antibody with an allogeneic NK cell may prove efficacious.”

The 7th Annual CAR-TCR Summit 2022, held September 19-22 in Boston, Massachusetts, brought together industry, academia, and patient advocacy groups to showcase emerging data and technologies in the oncology space, as well as to discuss and brainstorm ongoing challenges and work to be done with cell therapies in the space.

One such company in attendance was Cytoimmune, which is developing chimeric antigen receptor (CAR) natural killer (NK) cell therapies for both solid tumors and acute myeloid leukemia. Its lead program is CYTO NK-102, a therapy developed by use of the company’s TRACK-NK platform that secretes interleukin-15, a CAR, and a bispecific killer engager molecule, for the potential treatment of non-small cell lung cancer.

CGTLive spoke with Christine Coughlin, MD, PhD, chief executive officer, Cytoimmune, to learn more about the company’s technologies and programs. She discussed challenges with cell therapies in solid tumors as well as manufacturing challenges and advantages the company’s CAR-NK technology offers in the space.

Recent Videos
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.